LIPID-LOWERING EFFECT AND SAFETY OF ACIPIMOX IN HEMODIALYSIS-PATIENTS AND RENAL-TRANSPLANT RECIPIENTS

被引：2
作者：
TZANATOS, H [1 ]
KOUTSIKOS, D [1 ]
AGROYANNIS, B [1 ]
KAPETANAKI, A [1 ]
TSOUTSOS, D [1 ]
KONSTADINIDOU, I [1 ]
CHONDROS, K [1 ]
EXARCHOS, D [1 ]
机构：
[1] ARETAIEON UNIV HOSP,DEPT NEPHROL,GR-11528 ATHENS,GREECE
来源：
RENAL FAILURE | 1994年 / 16卷 / 03期
关键词：
Acipimox; Hemodialysis; Hyperlipidemia; Hypolipidemic drugs; Renal transplantation;
D O I：
10.3109/08860229409044879
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacy and safety of acipimox, an antilipolytic agent, were studied in 10 uremic patients under hemodialysis (group A) and in 8 renal transplant recipients with adequate renal function (group B). The medication was given for 20 weeks at a dose of 250 mg daily in both groups. Total serum cholesterol decreased significantly from 218.1 +/- 17.4 to 175.2 +/- 15.2 mg/dL (-19.7%) in group A and from 261.2 +/- 16.5 to 215.3 +/- 26.9 mg/dL (-17.6%) in group B; as did serum triglycerides, from 206.7 +/- 26.9 to 146.9 +/- 17.6 mg/dL (-29%) in group A and from 168.2 +/- 20.6 co 111.3 +/- 12.4 mg/dL (-33.8%) in group B. Low-density lipoprotein (LDL)-cholesterol and very low-density lipoprotein (VLDL)-cholesterol were also decreased significantly (LDL-C by -27% and -25%, and VLDL-C by -29.2% and -33.8% in groups A and B, respectively). Furthermore, the high-density lipoprotein (HDL)-cholesterol was increased significantly, by +29.6% in group A and +18% in group B. The apolipoproteins Ape-Al and Apo-A2 were decreased in Group A but not in group B. The Apo-B was decreased in group B. Serum CPK (total and muscle fraction), total bilirubin, SGPT, SGOT, alkaline phosphatase, gamma GT, LDL, a-Fp, and creatinine remained unchanged in both groups. Acipimox seems to be effective in the regulation of atherogenic lipid disorders in hemodialysis patients and renal transplant recipients, without any muscular damage or alteration of kidney and liver function.
引用
收藏
页码：391 / 405
页数：15
相关论文
共 42 条
  • [1] Kannel W.B., Castelli W.P., Gordon T., Cholesterol in the prediction of atherosclerotic desease: New perspectives based on the Framingham Study, Ann Intern Med, 90, pp. 85-91, (1979)
  • [2] Lees R.S., Lees A.M., High density lipoproteins and the risk of atherosclerosis, N Engl J Med, 306, pp. 1546-1548, (1982)
  • [3] Hully S.B., Rosenman R.H., Bawol R.D., Brand R.J., Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease, N Engl J Med, 302, pp. 1383-1389, (1980)
  • [4] Miller G.J., Miller N.E., Plasma high-density lipoprotein concentration and the development of ischaemic heart disease, Lancer, 1, pp. 16-19, (1975)
  • [5] Carlson L.A., Bottiger L.E., Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol, Lancer, 1, pp. 865-868, (1972)
  • [6] The lipid research clinics coronary primary prevention trial results I and 11. The relationship of reduction in incidence of coronary heart disease, Lipid Research Clinics Program. J Am Med Assoc, 351, 64, pp. 365-372, (1984)
  • [7] Rifkind B.M., Gemfibvozil, lipids and covonary risk, N Engl J Med, 317, pp. 1279-1282, (1987)
  • [8] Frick M.H., Elo O., Helsinki heart study, N Engl J Med, 317, pp. 1237-1246, (1987)
  • [9] Lindner A., Charra B., Sherrard D., Scribner B.H., Accelerated atherosclerosis in prolonged maintenance hemodialysis, N Engl J Med, 290, pp. 697-701, (1974)
  • [10] Haire H.M., Sherrard D.J., Scordapane D., Curtis F.K., Bruzell J.D., Smoking, hypertention and mortality in a maintenance dialysis population, Cordiovasc Med, 7, pp. 1163-1168, (1987)
12345